Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow Quality Index
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow Quality Index of 1.87x as of June 2026. Operating cash flow of $47.46 Million exceeds net income of $25.43 Million, indicating high earnings quality where cash backs reported profits. Explore Kiniksa Pharmaceuticals Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Kiniksa Pharmaceuticals Ltd Cash Flow Quality Index (2022–2023)
Historical Cash Flow Quality Index for Kiniksa Pharmaceuticals Ltd across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see KNSA cash flow metrics.
Annual Cash Flow Quality Index for Kiniksa Pharmaceuticals Ltd (2022–2023)
Year-by-year earnings quality comparison for Kiniksa Pharmaceuticals Ltd.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.94x | $13.30 Million | $14.08 Million | ▲ +2882.1% |
| 2022 | 0.03x | $5.81 Million | $183.36 Million | — |